Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Sci Transl Med. 2012 Feb 29;4(123):123ra24. doi: 10.1126/scitranslmed.3003500.
Ebola virus causes a fulminant infection in humans resulting in diffuse bleeding, vascular instability, hypotensive shock, and often death. Because of its high mortality and ease of transmission from human to human, Ebola virus remains a biological threat for which effective preventive and therapeutic interventions are needed. An understanding of the mechanisms of Ebola virus pathogenesis is critical for developing antiviral therapeutics. Here, we report that productive replication of Ebola virus is modulated by the c-Abl1 tyrosine kinase. Release of Ebola virus-like particles (VLPs) in a cell culture cotransfection system was inhibited by c-Abl1-specific small interfering RNA (siRNA) or by Abl-specific kinase inhibitors and required tyrosine phosphorylation of the Ebola matrix protein VP40. Expression of c-Abl1 stimulated an increase in phosphorylation of tyrosine 13 (Y(13)) of VP40, and mutation of Y(13) to alanine decreased the release of Ebola VLPs. Productive replication of the highly pathogenic Ebola virus Zaire strain was inhibited by c-Abl1-specific siRNAs or by the Abl-family inhibitor nilotinib by up to four orders of magnitude. These data indicate that c-Abl1 regulates budding or release of filoviruses through a mechanism involving phosphorylation of VP40. This step of the virus life cycle therefore may represent a target for antiviral therapy.
埃博拉病毒在人类中引起暴发性感染,导致弥散性出血、血管不稳定、低血压性休克,常导致死亡。由于其高死亡率和易于在人与人之间传播,埃博拉病毒仍然是一种生物威胁,需要有效的预防和治疗干预措施。了解埃博拉病毒发病机制对于开发抗病毒治疗方法至关重要。在这里,我们报告称,c-Abl1 酪氨酸激酶调节埃博拉病毒的有效复制。在细胞培养共转染系统中,埃博拉病毒样颗粒 (VLP) 的释放被 c-Abl1 特异性小干扰 RNA (siRNA) 或 Abl 特异性激酶抑制剂抑制,并需要埃博拉基质蛋白 VP40 的酪氨酸磷酸化。c-Abl1 的表达刺激 VP40 的酪氨酸 13 (Y13) 的磷酸化增加,而 Y13 突变为丙氨酸会降低埃博拉 VLP 的释放。高度致病性的扎伊尔型埃博拉病毒的有效复制被 c-Abl1 特异性 siRNA 或 Abl 家族抑制剂 nilotinib 抑制多达四个数量级。这些数据表明,c-Abl1 通过涉及 VP40 磷酸化的机制调节丝状病毒的出芽或释放。因此,该病毒生命周期的这一步可能代表抗病毒治疗的靶点。